Product news

Share this article:

An FDA advisory panel voted that a long-acting, injectable form of Eli Lilly's best-selling drug, the antipsychotic olanzapine, is safe enough for use in some patients with schizophrenia. But panel members shared concerns raised by the FDA that Zyprexa LAI was associated with excessive sedation.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.